[Antibody formation and resistance in dogs vaccinated intravenously and subcutaneously against distemper and Rubarth's disease].
The results of the vaccination of dogs with Canivac F (distemper vaccine) and Canivac FH (distemper) hepatitis vaccine, are presented. The Canivac F vaccine was injected intravenously (i.v.) to 8 dogs, intramuscularly (i.m.) to 1 dog and subcutaneously (s.c.) to 1 dog. The Canivac FH was administered i.v. to 19 dogs, i.m. to 1 dog and s.c. to 18 dogs. All the dogs displayed no-postvaccination signs. Distemper antibodies were observed in blood sera of all dogs vaccinated with Canivac F after 9-10 and 20-21 days. In sera of dogs vaccinated with Canivac FH, distemper, antibodies were present in 14 of 18 serum samples after 9-10 days and in 26 of 27 samples after 20-21 days. The antibody titre did not depend on the vaccination route. The peak of antibody titre was observed after 37 to 51 days after vaccination. The hepatitis antibodies in dogs vaccinated with Canivac FH were found in 15 of 17 animals after 9-10 days, and in all 27 dogs examined after 20-21 days. On the basis of an intracerebral challenge with virulent distemper virus and by intraperitoneal challenge with virulent dog's hepatitis virus (Rubarth's disease), it was demonstrated that all the vaccinated dogs acquired the full immunity. In addition, it was found  that vaccinated dogs kept in the environment contaminated naturally with Rubarth's disease virus were also resistant to the disease. All the non-vaccinated dogs were still susceptible to distemper or hepatitis infections. On the strength of the analysis of the obtained results and our previous studies, it can be assumed that Canivac F and FH vaccines produced in Poland are harmless and show a high immunogenic activity.
D000256:Adenoviridae / Q000276:immunology; D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis*; D004216:Distemper / Q000517:prevention & control*; D004285:Dogs; D006522:Hepatitis, Infectious Canine / Q000517:prevention & control*; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D009975:Orthomyxoviridae / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage*
D000914:Antibodies, Viral; D014765:Viral Vaccines
Wystepowanie przeciwciałl i odporności u psów szczepionych dozylnie i podskórnie przeciwko nosówce i chorobie Rubartha